Mode
Text Size
Log in / Sign up
Phase 2 N=230 Randomized Double-blind Treatment

A Study Evaluating the Safety and Efficacy of BGC20-0582 Lice Treatment Gel for Head Lice Infestation

Pediculus Humanus Capitis · Head Lice

Enrolled (actual)
230
Serious AEs
0.0%
Results posted
Dec 2010
Primary outcome: Primary: Clinical Cure — 30; 28; 35; 32 Participants

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
Placebo (Drug); BGC20-0582 (Drug)
Age
Pediatric, Adult, Older Adult · 2+ yrs
Sex
All
Sponsor
Boston Scientific Corporation
Primary completion
May 2008

Outcome Measures

OutcomeResultp-value
PRIMARY
Clinical Cure
30; 28; 35; 32

Summary

The main purpose of this study is to investigate the safety and efficacy of an investigational treatment for head lice infestation against a placebo.

Eligibility Criteria

Inclusion Criteria

  • The subject and/or his/her parent/legal guardian have provided written informed consent, and, if appropriate, the child has provided assent.
  • Male or female subjects who are between the ages of 2 years (24 months) and 70 years old when consent is signed.
  • Infestation with head lice as demonstrated by the presence of live lice prior to first treatment.
  • Willing and able to attend all study visits as scheduled.
  • Females of childbearing potential must have a negative urine pregnancy test at screening and before receiving a second treatment, if necessary.

Exclusion Criteria

  • Subject and/or legal guardian has not signed informed consent.
  • Subject was treated for pediculosis within 2 weeks prior to the screening evaluation.
  • Subject with an infestation of body lice or pubic lice.
  • Subject is suffering from a condition likely to require medical attention, including administration of oral or systemic antibiotics, oral or systemic corticosteroids, or any other treatment, which in the opinion of the investigator and visiting physician could influence the results of the study.
  • Subject with other diagnoses which, in the opinion of the investigator, would interfere with efficacy or safety assessments or would preclude study participation.
  • Subject with very short (shaved) hair.
  • Subject who will not be available for follow up visits.
  • Subject has been treated with a systemic antibiotic within the previous two weeks before screening.
  • Subject has been previously enrolled in any clinical study within the past 30 days; subject may not participate in another study while participating in this study.
  • Subject with history of allergy/sensitivity to active ingredient or related products; or any ingredients commonly included in hair products such as shampoos, hair conditioners, or styling aids.
  • Pregnant and/or nursing females.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00528021). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search